Everything NICE has said on renal (kidney) cancer in an interactive flowchart
Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)
Evidence-based recommendations on axitinib (Inlyta) for treating advanced renal cell carcinoma (RCC) (kidney cancer) when prior systemic treatment has failed
Evidence-based recommendations on percutaneous cryotherapy for renal (kidney) cancer
Evidence-based recommendations on irreversible electroporation (IRE) for treating renal (kidney) cancer
Evidence-based recommendations on percutaneous radiofrequency ablation for treating renal (kidney) cancer
Evidence-based recommendations on laparoscopic cryotherapy (keyhole surgery to destroy cancer cells by freezing) for treating renal (kidney) cancer
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma (kidney cancer) after previous treatment
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma (kidney cancer) in adults
Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma (kidney cancer) in adults
In development [GID-TA10189] Expected publication date: 15 May 2019
Evidence-based recommendations on tivozanib (Fotivda) for previously untreated advanced renal cell carcinoma (RCC/kidney cancer) in adults
Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma (RCC/kidney cancer) in adults
Evidence-based recommendations on laparoscopic nephrectomy (including nephroureterectomy; keyhole surgery to remove a kidney)
Evidence-based recommendations on sunitinib (Sutent) for the first-line treatment of advanced and/or metastatic renal cell carcinoma
In development [GID-TA10414] Expected publication date: 01 April 2020
In development [GID-TA10229] Expected publication date: 05 February 2020
Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma
This guideline covers preventing, detecting, and managing acute kidney injury in children (aged above 1 month and below 12 years), young people (aged 12 to 17 years) and adults (aged 18 years or older). It aims to improve assessment and detection by non-specialist clinicians, and specifies when they should refer people to specialist services. This will reduce the chance of death or complications for people at risk of acute kidney injury.
This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. Acute kidney injury is sudden damage to the kidneys, which can sometimes result in kidney failure. The quality standard includes assessment by non-specialists and when to refer to specialist services. It describes high-quality care in priority areas for improvement.
Everything NICE has said on kidney (renal) conditions in an interactive flowchart
This guideline covers safe and effective prescribing of strong opioids for pain relief in adults with advanced and progressive disease. It aims to clarify the clinical pathway for prescribing and help to improve pain management and patient safety. Care during the last 2 to 3 days of life is covered by care of dying adults in the last days of life.
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
This guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
This guideline covers the diagnosis and management of venous thromboembolic diseases in adults (aged 18 and over), and the role of thrombophilia testing. It aims to clarify which diagnostic tests should be used, reduce variation in pharmacological therapies, and provide guidance on when thrombophilia testing is useful.
This quality standard covers renal replacement therapy services for adults with kidney failure. It includes treatment options, such as dialysis and kidney transplant. It describes high-quality care in priority areas for improvement.
This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.
This guideline covers diagnosing, assessing, managing and monitoring anaemia in people with chronic kidney disease. It aims to improve care for people with chronic kidney disease by specifying how to assess when their anaemia needs treating, and by making detailed recommendations on treatment with erythropoietic stimulating agents (ESAs) and iron. It also covers detecting and managing ESA-resistant anaemia.
Evidence-based recommendations on single-port laparoscopic nephrectomy (‘keyhole’ surgery) to remove a kidney
Evidence-based recommendations on laparoscopic partial nephrectomy (keyhole surgery to remove kidney tumours)
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults
This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Evidence-based recommendations on immunosuppressive therapy for kidney transplant in children and young people
Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors
Everything NICE has said on urogenital conditions in an interactive flowchart
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults
Everything NICE has said on the recognition, diagnosis and early management of sepsis in an interactive flowchart
Evidence-based recommendations on irreversible electroporation (IRE) for treating liver metastases (secondary cancers)
Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
This guideline covers the recognition, diagnosis and early management of sepsis for all populations. The guideline committee identified that the key issues to be included were: recognition and early assessment, diagnostic and prognostic value of blood markers for sepsis, initial treatment, escalating care, identifying the source of infection, early monitoring, information and support for patients and carers, and training and education.
dialysis or die. One patient in 5 has aHUS affecting organs other than the kidneys, most commonly the brain or heart. 2.2 aHUS can occur...
This quality standard covers encouraging physical activity in people of all ages who are in contact with the NHS, including staff, patients and carers. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)
This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.
Evidence-based recommendations on irreversible electroporation (IRE) for treating primary lung cancer and metastases in the lung
Evidence-based recommendations on irreversible electroporation (IRE) for treating primary liver cancer
This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.